ascopubs.org

Mismatch repair (MMR) and base excision repair (BER) protein expression correlates with clinical response to dacarbazine (DTIC)/temozolomide (TMZ) therapy of patients with ...

Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104 No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2006 ASCO ...
ascopubs.org

Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing

Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer To predict MMR-D, we adapted methods ...
The New England Journal of Medicine

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in ...
Medscape

Mismatch Repair Status Linked to Endometrial Cancer Outcomes, Real-World Study Reveals

A retrospective study found that patients with mismatch repair (MMR)-deficient advanced or recurrent endometrial cancer had numerically longer overall survival (OS) than those with MMR-proficient ...
The New England Journal of Medicine

Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer

Mismatch repair–deficient (dMMR) tumors can be found in 10 to 15% of patients with nonmetastatic colon cancer. In these patients, the efficacy of chemotherapy is limited. The use of neoadjuvant ...